science.bio dihexa | | 1401708-83-5 Dihexa 1mL(10 mM in DMSO)

European Neuropsychopharmacology, 19(S9), S681S682

Because of BPC-157s original gastric source, the oral version (as a mouth spray) is being used for GERD, stomach ulcers, Crohns disease, ulcerative colitis and leaky gut

What to Expect Over Time Weeks 12: Decrease in inflammation and discomfort Early improvements in digestion and gut comfort (oral form) Weeks 36: Improved tissue repair and mobility Enhanced recovery and energy levels Weeks 612+: Long-term improvements in joint, tendon, and muscle strength Sustained gut health and systemic support Results vary depending on condition, severity, and consistency of use

106,127,128 Intriguingly, both enzymatic and non-enzymatic antioxidant system components exhibit their effects in coordination with each other to contribute to redox homeostasis and cell fate using NADPH as the ultimate donor of reductive power

It activates GLP-1R (class B GPCR) to stimulate Gs-cAMP-PKA signaling in pancreatic beta cells for glucose-dependent insulin secretion, suppress appetite through hypothalamic GLP-1R activation, and slow gastric emptying via vagal pathways